research use only
Cat.No.S2854
| Related Targets | CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas |
|---|---|
| Other Cannabinoid Receptor Inhibitors | AM1241 AM251 Org 27569 6-Iodopravadoline (AM630) Otenabant (CP-945598) HCl GW842166X CID16020046 WIN 55, 212-2 mesylate Pregnenolone monosulfate sodium RTICBM-189 |
|
In vitro |
DMSO
: 22 mg/mL
(51.53 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 426.89 | Formula | C23H23ClN2O4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 2854-32-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | IMMA | Smiles | CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)N4CCOCC4 | ||
| Targets/IC50/Ki |
CB2
435 nM(Ki)
|
|---|---|
| In vitro |
BML-190 has 50-fold selectivity for CB2 receptors over CB1 receptors. In HEK-293 cells stably expressing the human CB2 receptor, this compound potentiates the forskolin-stimulated accumulation of cAMP. It reduces the basal levels of inositol phosphate production in cells expressing the CB2 receptor. 10 μM of this chemical decreases inositol phosphates accumulation by 38%. This compound is an aminoalkylindole. It is found to yield at least 15 metabolic products. It diminishes LPS-induced NO and IL-6 production in a concentration-dependent manner. This compound also inhibits LPS-induced PGE2 production and COX-2 induction.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01123655 | Completed | Rheumatoid Arthritis |
VA Office of Research and Development |
October 2009 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.